Review



primary cd14 human peripheral blood monocytes hpbms  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    PromoCell primary cd14 human peripheral blood monocytes hpbms
    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated <t>CD14</t> + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Primary Cd14 Human Peripheral Blood Monocytes Hpbms, supplied by PromoCell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+cd14+human+peripheral+blood+monocytes+hpbms/Human+CD14%2B+Monocytes+(hMoCD14%2B-PB)%2C+Cell+Pellet+in+RNAlater/pmc12847883-228-2-13
    Average 93 stars, based on 1 article reviews
    primary cd14 human peripheral blood monocytes hpbms - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness"

    Article Title: Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness

    Journal: Cell Death & Disease

    doi: 10.1038/s41419-025-08363-9

    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated CD14 + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Figure Legend Snippet: A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated CD14 + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).

    Techniques Used: Expressing, Derivative Assay

    Related Articles

    Expressing:

    Article Title: Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness
    Article Snippet: The cells were treated with indicated concentrations of dexamethasone (Merck; #D4902), the glucocorticoid receptor (GR)-specific antagonist relacorilant (CORT125134, kind gift from Corcept Therapeutics; Menlo Park, CA, USA), the SAA1 inhibitor SGA360 (10 mM, MedChemExpress; #HY-122208), and/or the FLT-1 neutralizing antibody Icrucumab (30 μg/ml, MedChemExpress; #HY-P99364, and control antibody #HY-P99003).The cells were treated with indicated concentrations of dexamethasone (Merck; #D4902), the glucocorticoid receptor (GR)-specific antagonist relacorilant (CORT125134, kind gift from Corcept Therapeutics; Menlo Park, CA, USA), the SAA1 inhibitor SGA360 (10 mM, MedChemExpress; #HY-122208), and/or the FLT-1 neutralizing antibody Icrucumab (30 μg/ml, MedChemExpress; #HY-P99364, and control antibody #HY-P99003).. In addition, primary CD14 + human peripheral blood monocytes (hPBMs) were purchased from PromoCell (#C-14110) as a single-donor cell pellet stored in RNA later ® .. Primary human monocyte-derived macrophages (hMDMs) were also purchased from PromoCell as non-activated, fully polarized M1 (GM-CSF) or M2 (M-CSF) cells (#C-12914, #C-12915; respectively).Primary human monocyte-derived macrophages (hMDMs) were also purchased from PromoCell as non-activated, fully polarized M1 (GM-CSF) or M2 (M-CSF) cells (#C-12914, #C-12915; respectively).

    Article Title: Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness.
    Article Snippet: The cells were treated with indicated concentrations of dexamethasone (Merck; #D4902), the glucocorticoid receptor (GR)-specific antagonist relacorilant (CORT125134, kind gift from Corcept Therapeutics; Menlo Park, CA, USA), the SAA1 inhibitor SGA360 (10 mM, MedChemExpress; #HY-122208) and/or the FLT-1 neutralizing antibody Icrucumab (30 μg/ml, MedChemExpress; #HY-P99364, and control antibody #HY-P99003 ).The cells were treated with indicated concentrations of dexamethasone (Merck; #D4902), the glucocorticoid receptor (GR)-specific antagonist relacorilant (CORT125134, kind gift from Corcept Therapeutics; Menlo Park, CA, USA), the SAA1 inhibitor SGA360 (10 mM, MedChemExpress; #HY-122208) and/or the FLT-1 neutralizing antibody Icrucumab (30 μg/ml, MedChemExpress; #HY-P99364, and control antibody #HY-P99003 ).. In addition, primary CD14+ human peripheral blood monocytes (hPBMs) were purchased from PromoCell (#C-14110) as a single-donor cell pellet stored in RNAlater®.. Primary human monocyte-derived macrophages (hMDMs) were also purchased from PromoCell as nonactivated fully polarized M1 (GM-CSF) or M2 (M-CSF) cells (#C-12914, #C-12915; respectively).Primary human monocyte-derived macrophages (hMDMs) were also purchased from PromoCell as nonactivated fully polarized M1 (GM-CSF) or M2 (M-CSF) cells (#C-12914, #C-12915; respectively).

    Derivative Assay:

    Article Title: Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness
    Article Snippet: The cells were treated with indicated concentrations of dexamethasone (Merck; #D4902), the glucocorticoid receptor (GR)-specific antagonist relacorilant (CORT125134, kind gift from Corcept Therapeutics; Menlo Park, CA, USA), the SAA1 inhibitor SGA360 (10 mM, MedChemExpress; #HY-122208), and/or the FLT-1 neutralizing antibody Icrucumab (30 μg/ml, MedChemExpress; #HY-P99364, and control antibody #HY-P99003).The cells were treated with indicated concentrations of dexamethasone (Merck; #D4902), the glucocorticoid receptor (GR)-specific antagonist relacorilant (CORT125134, kind gift from Corcept Therapeutics; Menlo Park, CA, USA), the SAA1 inhibitor SGA360 (10 mM, MedChemExpress; #HY-122208), and/or the FLT-1 neutralizing antibody Icrucumab (30 μg/ml, MedChemExpress; #HY-P99364, and control antibody #HY-P99003).. In addition, primary CD14 + human peripheral blood monocytes (hPBMs) were purchased from PromoCell (#C-14110) as a single-donor cell pellet stored in RNA later ® .. Primary human monocyte-derived macrophages (hMDMs) were also purchased from PromoCell as non-activated, fully polarized M1 (GM-CSF) or M2 (M-CSF) cells (#C-12914, #C-12915; respectively).Primary human monocyte-derived macrophages (hMDMs) were also purchased from PromoCell as non-activated, fully polarized M1 (GM-CSF) or M2 (M-CSF) cells (#C-12914, #C-12915; respectively).

    Article Title: Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness.
    Article Snippet: The cells were treated with indicated concentrations of dexamethasone (Merck; #D4902), the glucocorticoid receptor (GR)-specific antagonist relacorilant (CORT125134, kind gift from Corcept Therapeutics; Menlo Park, CA, USA), the SAA1 inhibitor SGA360 (10 mM, MedChemExpress; #HY-122208) and/or the FLT-1 neutralizing antibody Icrucumab (30 μg/ml, MedChemExpress; #HY-P99364, and control antibody #HY-P99003 ).The cells were treated with indicated concentrations of dexamethasone (Merck; #D4902), the glucocorticoid receptor (GR)-specific antagonist relacorilant (CORT125134, kind gift from Corcept Therapeutics; Menlo Park, CA, USA), the SAA1 inhibitor SGA360 (10 mM, MedChemExpress; #HY-122208) and/or the FLT-1 neutralizing antibody Icrucumab (30 μg/ml, MedChemExpress; #HY-P99364, and control antibody #HY-P99003 ).. In addition, primary CD14+ human peripheral blood monocytes (hPBMs) were purchased from PromoCell (#C-14110) as a single-donor cell pellet stored in RNAlater®.. Primary human monocyte-derived macrophages (hMDMs) were also purchased from PromoCell as nonactivated fully polarized M1 (GM-CSF) or M2 (M-CSF) cells (#C-12914, #C-12915; respectively).Primary human monocyte-derived macrophages (hMDMs) were also purchased from PromoCell as nonactivated fully polarized M1 (GM-CSF) or M2 (M-CSF) cells (#C-12914, #C-12915; respectively).



    Similar Products

    primary cd14 human peripheral blood monocytes hpbms  (PromoCell)
    93
    PromoCell primary cd14 human peripheral blood monocytes hpbms
    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated <t>CD14</t> + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).
    Primary Cd14 Human Peripheral Blood Monocytes Hpbms, supplied by PromoCell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+cd14+human+peripheral+blood+monocytes+hpbms/Human+CD14%2B+Monocytes+(hMoCD14%2B-PB)%2C+Cell+Pellet+in+RNAlater/pmc12847883-228-2-13
    Average 93 stars, based on 1 article reviews
    primary cd14 human peripheral blood monocytes hpbms - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated CD14 + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).

    Journal: Cell Death & Disease

    Article Title: Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness

    doi: 10.1038/s41419-025-08363-9

    Figure Lengend Snippet: A Schematic of DEX treatment during macrophage differentiation (day 0–6). B mRNA expression of the M1 markers CCR7 , CD80 , PTGS2 , and IL1B ( n = 3 [ CCR7 ], 4), and C ) M2 markers CD163 and MRC1 ( n = 3). D Schematic of DEX treatment during macrophage M1 polarization (day 6–8). E mRNA expression of M1 markers ( n = 3 [ PTGS2, IL1B ], 5 [ CCR7, CD80 ]), and F ) M2 markers ( n = 3, 4 [M2 0, M1 0]). H Schematic of DEX treatment of M1 polarized macrophages (days 8–10). I mRNA expression of M1 markers ( n = 3) and J M2 markers ( n = 3). M2 macrophages were not DEX-treated, and comparisons were to M1 polarized macrophages at 0 nM DEX in ( A )–( J ). K mRNA expression of the M2 markers CD163 and MRC1 , and NR3C1 (GR) in primary human peripheral blood monocyte-derived macrophages (hMDMs) after 2 days of vehicle or 100 nM DEX treatment. All mRNA expression was relative to untreated THP-1 cells and normalized to the housekeeping gene HPRT1 in B , C , E , F , I , J , and relative to untreated CD14 + hPBM cells and normalized to HPRT1 in K. Bars represent mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons correction in B , C , E , F , I , J , and using Student’s unpaired t -test in ( K ).

    Article Snippet: In addition, primary CD14 + human peripheral blood monocytes (hPBMs) were purchased from PromoCell (#C-14110) as a single-donor cell pellet stored in RNA later ® .

    Techniques: Expressing, Derivative Assay